[阿片类药物引起的便秘:管理和治疗的最新情况]
Alice Boilève1, Charlotte Desprez2, Florian Scotté3
1Département d'oncologie médicale, Gustave-Roussy, université Paris-Saclay, 94800 Villejuif, France.
Bulletin du cancer
|February 26, 2025
概括
阿片类药物引起的便秘 (OIC) 是治疗疼痛的常见副作用. 外围作用的μ-阿片类受体抗剂 (PAMORA) 提供有针对性的缓解,而不会影响疼痛控制.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 阿片类药物对于疼痛管理至关重要,特别是在癌症治疗中.
- 阿片类药物引起的便秘 (OIC) 是常见的胃肠道不良影响.
- OIC可能会对患者的舒适性和治疗坚持产生负面影响.
研究的目的:
- 审查OIC的定义,病理生理学,流行病学和诊断标准.
- 详细介绍OIC的风险因素和诊断工作.
- 探索OIC对阿片类药物治疗的影响,并概述治疗策略.
主要方法:
- 文献综述侧重于OIC定义,病理生理学和流行病学.
- 分析诊断标准,风险因素和必要的测试.
- 评估治疗选择,包括非药物和药物疗法.
主要成果:
- OIC是一个与肠道中μ受体活性相关的重要问题.
- 2016年为OIC建立了一个共识定义.
- 外周作用的μ-阿片类受体对抗剂 (PAMORA) 可以有效治疗OIC.
结论:
- 了解OIC的机制和影响对于支持性护理至关重要.
- 帕莫拉代表了针对OIC的向治疗选择.
- 综合管理策略对于优化阿片类药物治疗和患者福祉至关重要.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
125
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
125
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
170
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
170
Drugs for Treatment of Diarrhea-Predominant IBS
140
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
140
Irritable Bowel Syndrome III: Medical and Nursing Management
137
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
137
Analgesia and Pain Management
422
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
422
Opioid Analgesics: Synthetic and Semisynthetic Opioids
204
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
204


